137 related articles for article (PubMed ID: 38670257)
1. A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023.
Patel R; Vhora A; Jain D; Patel R; Khunt D; Patel R; Dyawanapelly S; Junnuthula V
Drug Discov Today; 2024 Jun; 29(6):103993. PubMed ID: 38670257
[TBL] [Abstract][Full Text] [Related]
2. FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010-2020.
Rathore AS; Li Y; Chhabra H; Lohiya A
J Pharm Innov; 2022 Aug; ():1-10. PubMed ID: 35992018
[TBL] [Abstract][Full Text] [Related]
3. Human Medicines Recall Announcements in Saudi Arabia Between 2017 and 2022: An Analysis of Saudi Food and Drug Authority (SFDA) Reports.
Almutairi M; Algabbani A; Alasiri A; Alhomaidan A; Alqahtani AS
Ther Innov Regul Sci; 2024 Jul; 58(4):689-695. PubMed ID: 38546962
[TBL] [Abstract][Full Text] [Related]
4. Moulds associated with contaminated ocular and injectable drugs: FDA recalls, epidemiology considerations, drug shortages, and aseptic processing.
Ahearn DG; Stulting RD
Med Mycol; 2018 Jun; 56(4):389-394. PubMed ID: 29420758
[TBL] [Abstract][Full Text] [Related]
5. Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare.
Gillette M; Taylor A; Butulija D; Kadiyala H; Jneid H
Cardiovasc Drugs Ther; 2020 Aug; 34(4):579-584. PubMed ID: 32318933
[TBL] [Abstract][Full Text] [Related]
6. Categorization and comparisons of drug recalls for manufacturers and compounders.
Mattingly AN; Mattingly TJ; Nguyen Phan AL; Negash K
J Am Pharm Assoc (2003); 2022; 62(4):1344-1350. PubMed ID: 35422393
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of FDA drug recalls: A 30-month analysis.
Hall K; Stewart T; Chang J; Freeman MK
Am J Health Syst Pharm; 2016 Feb; 73(4):235-40. PubMed ID: 26843501
[TBL] [Abstract][Full Text] [Related]
8. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
[TBL] [Abstract][Full Text] [Related]
9. A Nontrivial Analysis of Patient Safety Risk from Parenteral Drug- and Medical Device-Borne Endotoxin.
Tidswell EC
Drugs R D; 2023 Mar; 23(1):65-76. PubMed ID: 36829051
[TBL] [Abstract][Full Text] [Related]
10. Drug and medical device product failures and the stability of the pharmaceutical supply chain.
Livingston AN; Mattingly TJ
J Am Pharm Assoc (2003); 2021; 61(1):e119-e122. PubMed ID: 32753251
[TBL] [Abstract][Full Text] [Related]
11. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
12. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2020 Jul; 54(4):925-931. PubMed ID: 32557315
[TBL] [Abstract][Full Text] [Related]
13. Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.
Wang L; Zheng H; Ren X; Sun H
Ther Innov Regul Sci; 2016 May; 50(3):312-318. PubMed ID: 30227064
[TBL] [Abstract][Full Text] [Related]
14. The Identification of Quality Risk Factors for Non-biological Complex Drugs and Epilepsy Drugs Using Statistical Analysis of Formulation-Based Recalls in the USA.
Kerstiens EA; Byrn SR; Clase KL
AAPS PharmSciTech; 2021 Dec; 23(1):19. PubMed ID: 34904204
[TBL] [Abstract][Full Text] [Related]
15. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
Nguyen D; Seoane-Vazquez E; Rodriguez-Monguio R; Montagne M
BMC Health Serv Res; 2013 Jan; 13():27. PubMed ID: 23339419
[TBL] [Abstract][Full Text] [Related]
16. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
Ronquillo JG; Zuckerman DM
Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
[TBL] [Abstract][Full Text] [Related]
17. Blood product recalls in the United States.
McCullough J; Riley E; Lindgren B; Pulkrabek S; Hall R; Riley W
Transfusion; 2014 Sep; 54(9):2276-82. PubMed ID: 24863173
[TBL] [Abstract][Full Text] [Related]
18. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
Steinwandter V; Herwig C
PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
[TBL] [Abstract][Full Text] [Related]
19. Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance.
Everhart AO; Sen S; Stern AD; Zhu Y; Karaca-Mandic P
JAMA; 2023 Jan; 329(2):144-156. PubMed ID: 36625811
[TBL] [Abstract][Full Text] [Related]
20. The nature and pattern of coronary stent recalls.
Kumar S; Innasimuthu AL; Marmur JD
J Invasive Cardiol; 2014 Sep; 26(9):433-6. PubMed ID: 25198486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
